Navigation Links
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Date:1/13/2010

y growing U.S. division of Octapharma AG

"The FDA orphan drug exclusivity approval for wilate® is an important aspect in Octapharma`s development of this drug," said Kim Bjornstrup, Vice Chairman Octapharma Group. "Orphan drug exclusivity confirms Octapharma's decision to focus exclusively on the treatment of von Willebrand patients. Wilate has a combination of two viral attenuation steps, high purity and a physiological 1:1 ratio of VWF and FVIII activity and is approved for treating all VWD patients including those with the most severe, type 3, disease."

About wilate®:

Wilate® is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD including pediatric patients in four prospective clinical trials utilizing both objective and subjective criteria.

On December 4, 2009, wilate® received FDA approval for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe VWD as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.(1) Wilate® is the first double virus inactivated VWF/FVIII (von Willebrand Factor/Factor FVIII), high-purity concentrate, utilizing the solvent/detergent (S/D) process and a special terminal dry-heating (TDH) system. The selected purification processes isolate the VWF/FVIII complex under highly protein-protecting conditions, resulting in a 1:1 ratio of VWF:RCo (ristocetin cofactor) and FVIII activities that is similar to normal plasma. Wilate® is exclusively derived from large pools of human pl
'/>"/>

SOURCE Octapharma AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
2. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
5. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
7. GeneGo Receives SBIR Grant
8. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
9. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
10. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
11. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 This BCC Research report ... of major players, market growth and size, and opportunities for ... and revenue through 2018. Patent analysis in the report focuses ... the U.S., Europe and ... - Define and discuss the global medical device technologies market. ...
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:9/18/2014)... LEXINGTON, Ky (Sept. 17, 2014) -- Two independent ... PhD, of the University of Kentucky, and Charles ... published important studies exploring the role that a ... cardiovascular disease. , According to Whiteheart, previous genome-wide ... as a factor that regulates a protein called ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... CAMBRIDGE, Massachusetts, U.S.A., September 18, 2014 -- BGI ... sequencing service to Denmark-based DLF-Trifolium and the Department ... University in an effort to develop a series ... genomic selection (GS) methods. , GS is a ... contrast to the traditional QTL-based selection, uses information ...
(Date:9/18/2014)... September 18, 2014 CRDF Global ... first ever digital edition – rich with videos, ... of how CRDF Global empowers scientists and innovators ... of government, corporate, foundation and individual supporters, CRDF ... innovators in research, training and entrepreneurship. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
Breaking Medicine News(10 mins):Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... to detect suspicious activity in airports, stadiums and other ... researcher who invented them to find and measure potentially ... professor of Computer Science and one of the world,s ... computer imaging, has received $400,000 from the National Institutes ...
... about the importance of eye assessments for babies during June,s ... 2 When should a parent schedule a comprehensive eye ... at 6 months, the average baby has reached a number ... the first eye and vision assessment. , , According ...
... for space headache to be established as a new ... astronauts, published in the June issue of Cephalalgia ... headaches are normally caused by space motion sickness, after ... no connection. "Our research shows that space flights ...
... device will facilitate single port access laparoscopic surgery , ... privately held biomaterials-based medical device company, announced today that ... and Drug Administration to market the InnoPort(TM) to facilitate ... The InnoPort is inserted into the abdomen to perform ...
... , - Free health clinics facing crisis of increasing demand, ... hand in helping make donation possible , , - ... banks in December , , RICHMOND, Va., June 2 ... announced today it is donating $1 million to free health ...
... ... at trial, and bring Attorneys state of the art fall prevention and protection training. ... (PRWEB) June ... settlements, assist representation at trial, and bring Attorneys state of the art fall prevention ...
Cached Medicine News:Health News:UCF researcher developing computer program to detect, measure brain tumors 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 3Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 4Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 5Health News:Researchers call for new space headache category following astronauts' survey 2Health News:Innovia Receives FDA Clearance For The InnoPort(TM) 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 3Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 4Health News:Fall Prevention/Protection - Slip and Fall Accredited Training for Legal Practices 2
5x6mm Loop, 2 Irrigation Ports at 10, 2 O'Clock, 18 Gauge Thin Walled 1.2mm Shaft; overall length 40mm; stainless steel...
... long, thick-walled cannula which contains a coaxial ... Helical Loop Basket and a Tip Deflecting ... the outer cannula to carry these two ... right atrium. (Requires a Handle for Tip ...
... a non-invasive, virtually pain-free alternative to conventional ... selected indications. With Leksell Gamma Knife C ... positioning improves the ability to mould the ... This allows a more selective irradiation and ...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: